Melatonin Improves Erythropoietin Hyporesponsiveness via Suppression of Inflammation.

Melatonin Improves Erythropoietin Hyporesponsiveness via Suppression of Inflammation. Rev Recent Clin Trials. 2019 May 28;: Authors: Hameed EN, Al Tukmagi HFH, Allami HCA Abstract BACKGROUND: Inadequate response to erythropoietin stimulating agents (ESA) despite of using relatively larger doses regimen represent a potential risk factor of cardiovascular (CV) related mortality in addition to health-care economic problems in anemic patients with chronic kidney disease (CKD). Erythropoietin (EPO) hyporesponsiveness related to inflammation has been increased progressively. Melatonin is well known as potent anti-inflammatory agent. Therefor the current study designed to evaluate whether melatonin could improve anemic patients response to EPO. METHOD: This single controlled clinical study carried out 41 CKD patient with hemoglobin (Hb) level less than 11g/dl divided randomly in 1:1 ratio into 2 groups, treatment group who received 5mg melatonin plus their regular treatments and control group who received their regular treatments only. Hematological and iron status parameters include Hb level, serum iron (S. iron), transferrin saturation ratio (TSAT) and serum ferritin (S. ferritin) in addition to inflammatory parameters that include tissue necrotic factor alfa (TNF-α), interleukin-1beta (IL-1β) and interleukin-6 (IL-6) was determined before and after 12 weeks of treatment. RESULTS: Melatonin remarkably increase Hb level w...
Source: Reviews on Recent Clinical Trials - Category: Cancer & Oncology Authors: Tags: Rev Recent Clin Trials Source Type: research